Expert consensus on the use of omalizumab in chronic urticaria in China
Chronic urticaria (CU) is a debilitating skin disease that lasts for more than 6 weeks with wheals and/or angioedema, including chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). In China, the prevalence of this disease is high, more than 1%, and on the rise. CU has a major...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-11-01
|
| Series: | World Allergy Organization Journal |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1939455121001046 |
| _version_ | 1818337373631545344 |
|---|---|
| author | Zuotao Zhao, MD, PhD Tao Cai, MD Hong Chen, MD Liuqing Chen, MD Yudi Chen, MD Xiang Gao, MD Xinghua Gao, MD Songmei Geng, MD Yinshi Guo, MD Fei Hao, MD Guodong Hao, MM Yan Hu, MD Hongzhong Jin, MD Zhehu Jin, MD Chengxin Li, MD Haili Li, MD Jie Li, MD Yanming Li, MD Yunsheng Liang, MD Guanghui Liu, MD Qiang Liu, MD Hai Long, MD Lin Ma, MD Yuanyuan Shang, MM Yuxin Song, MB Zhiqiang Song, MD Xiangyang Su, MD Haijing Sui, MD Qing Sun, MD Yuemei Sun, MB Jianping Tang, MD Xunliang Tong, MD Huiying Wang, MD Gang Wang, MD Lianglu Wang, MD Siqin Wang, MB Li Xiang, MD Ting Xiao, MD Zhiqiang Xie, MD. Leping Ye, MD Yongmei Yu, MM Chunlei Zhang, MD, PhD Litao Zhang, MD Shuchen Zhang, MD, PhD Rui Zheng, MD Lili Zhi, MM Wei Zhou, MD Ying Zou, MD Marcus Maurer, MD |
| author_facet | Zuotao Zhao, MD, PhD Tao Cai, MD Hong Chen, MD Liuqing Chen, MD Yudi Chen, MD Xiang Gao, MD Xinghua Gao, MD Songmei Geng, MD Yinshi Guo, MD Fei Hao, MD Guodong Hao, MM Yan Hu, MD Hongzhong Jin, MD Zhehu Jin, MD Chengxin Li, MD Haili Li, MD Jie Li, MD Yanming Li, MD Yunsheng Liang, MD Guanghui Liu, MD Qiang Liu, MD Hai Long, MD Lin Ma, MD Yuanyuan Shang, MM Yuxin Song, MB Zhiqiang Song, MD Xiangyang Su, MD Haijing Sui, MD Qing Sun, MD Yuemei Sun, MB Jianping Tang, MD Xunliang Tong, MD Huiying Wang, MD Gang Wang, MD Lianglu Wang, MD Siqin Wang, MB Li Xiang, MD Ting Xiao, MD Zhiqiang Xie, MD. Leping Ye, MD Yongmei Yu, MM Chunlei Zhang, MD, PhD Litao Zhang, MD Shuchen Zhang, MD, PhD Rui Zheng, MD Lili Zhi, MM Wei Zhou, MD Ying Zou, MD Marcus Maurer, MD |
| author_sort | Zuotao Zhao, MD, PhD |
| collection | DOAJ |
| description | Chronic urticaria (CU) is a debilitating skin disease that lasts for more than 6 weeks with wheals and/or angioedema, including chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). In China, the prevalence of this disease is high, more than 1%, and on the rise. CU has a major impact on the quality of life (QoL) of patients who frequently experience sleep disturbance, depression, and anxiety. Nearly one-third of patients with CSU, in China, are resistant to second-generation H1-antihistamines (sgAHs), even at a fourfold dose (second line; off-label). Omalizumab is approved for the treatment of CSU treatment in Europe and shows remarkable efficacy and safety. In China, regulatory approval for the use of omalizumab is pending, and its use in clinical practice varies widely. Consensus on omalizumab CU treatment in China is urgently needed. The aim of this article is to propose a practical omalizumab treatment algorithm for the management of antihistamine-resistant CSU and CIndU in adults and special population including children and adolescents, and pregnant or breast feeding women, to guide daily clinical practice in China. In the development of this consensus, an expert group including mainly dermatologists, allergists, but also pulmonologists, ENTs, immunologists, and pediatricians in Allergic Disease Prevention and Control Committee, Chinese Preventive Medicine Association, reviewed the existing evidence and developed consensus on the use of omalizumab in CU patients from China. The goal of this consensus is to assist clinicians in making rational decisions in the management of refractory CU with omalizumab. The key clinical questions covered by the treatment algorithm are: 1) Omalizumab treatment routine strategy in both CSU and CIndU patients; 2) Recommended dose and treatment duration for different age stratification; 3) Treatment duration for CU patients with other allergic comorbidities; 4) Recommendation on omalizumab stopping strategy. |
| first_indexed | 2024-12-13T14:54:11Z |
| format | Article |
| id | doaj.art-9875079723964e719a0bcd96761f2778 |
| institution | Directory Open Access Journal |
| issn | 1939-4551 |
| language | English |
| last_indexed | 2024-12-13T14:54:11Z |
| publishDate | 2021-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | World Allergy Organization Journal |
| spelling | doaj.art-9875079723964e719a0bcd96761f27782022-12-21T23:41:16ZengElsevierWorld Allergy Organization Journal1939-45512021-11-011411100610Expert consensus on the use of omalizumab in chronic urticaria in ChinaZuotao Zhao, MD, PhD0Tao Cai, MD1Hong Chen, MD2Liuqing Chen, MD3Yudi Chen, MD4Xiang Gao, MD5Xinghua Gao, MD6Songmei Geng, MD7Yinshi Guo, MD8Fei Hao, MD9Guodong Hao, MM10Yan Hu, MD11Hongzhong Jin, MD12Zhehu Jin, MD13Chengxin Li, MD14Haili Li, MD15Jie Li, MD16Yanming Li, MD17Yunsheng Liang, MD18Guanghui Liu, MD19Qiang Liu, MD20Hai Long, MD21Lin Ma, MD22Yuanyuan Shang, MM23Yuxin Song, MB24Zhiqiang Song, MD25Xiangyang Su, MD26Haijing Sui, MD27Qing Sun, MD28Yuemei Sun, MB29Jianping Tang, MD30Xunliang Tong, MD31Huiying Wang, MD32Gang Wang, MD33Lianglu Wang, MD34Siqin Wang, MB35Li Xiang, MD36Ting Xiao, MD37Zhiqiang Xie, MD.38Leping Ye, MD39Yongmei Yu, MM40Chunlei Zhang, MD, PhD41Litao Zhang, MD42Shuchen Zhang, MD, PhD43Rui Zheng, MD44Lili Zhi, MM45Wei Zhou, MD46Ying Zou, MD47Marcus Maurer, MD48Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China; Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China; National Clinical Research Center for Skin and Immune Diseases, Beijing, China; Corresponding author. Department of Dermatology and Venereology, Peking University First Hospital, Xishiku Avenue No. 8, Beijing, PR China.Department of Dermatology and Venerology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Dermatology and Venerology, Tianjin People's Hospital, Tianjin Union Medical Center, Tianjin, ChinaDepartment of Dermatology and Venerology, Wuhan No.1 Hospital, Wuhan, ChinaDepartment of Dermatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, ChinaDepartment of Allergy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, ChinaDepartment of Dermatology and Venerology, The First Hospital of China Medical University, Shenyang, ChinaDepartment of Dermatology and Venerology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, ChinaDepartment of Allergy, Renji Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, ChinaDepartment of Dermatology and Venerology, The Third Affiliated Hospital of Chongqing Medicine University, Chongqing, ChinaDepartment of Allergy, Tangshan Gongren Hospital, Tangshan, ChinaDepartment of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, ChinaDepartment of Dermatology and Venerology, Peking Union Medical College Hospital, Chinese Academy Medical Science, Peking Union Medical College, Beijing, ChinaDepartment of Dermatology and Venerology, Yanbian University Hospital (Yanbian Hospital), Jilin, ChinaDepartment of Dermatology and Venerology, The First Medical Center, Chinese PLA General Hospital, Beijing, ChinaDepartment of Ophthalmology, Peking University First Hospital, Beijing, ChinaDepartment of Dermatology and Venerology, Xiangya Hospital Central South University, Changsha, ChinaDepartment of Respiratory and Critical Care Medicine, Bejing Hospital, Beijing, ChinaDepartment of Dermatology and Venerology, Dermatology Hospital of Southern Medical University, Guangdong Provincial Dermatology Hospital, Guangdong, ChinaDepartment of Allergy, ZhongNan Hospital of Wuhan University, Wuhan, ChinaDepartment of Dermatology and Venerology, The Second Hospital of Hebei Medical University, Shijiazhuang, ChinaDepartment of Dermatology and Venerology, The Second Xiangya Hospital of Central South University, Changsha, ChinaDepartment of Dermatology and Venerology, Beijing Children's Hospital Capital Medical University, Beijing, ChinaDepartment of Dermatology and Venerology, General Hospital of Ningxia Medical University, Yinchuan, ChinaDepartment of Allergy, Harbin Children's Hospital, Harbin, ChinaDepartment of Dermatology and Venerology, The First Affiliated Hospital of Third Military Medical University, Chongqing, ChinaDepartment of Dermatology and Venerology, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, ChinaDepartment of Otorhinolaryngology Head and Neck Surgery, Peking University First Hospital, ChinaDepartment of Dermatology and Venerology, Qilu Hospital, Shandong University, Jinan, ChinaDepartment of Allergy, Yantai Yuhuangding Hospital, Yantai, ChinaDepartment of Dermatology and Venerology, Hunan Children's Hospital, Changsha, ChinaDepartment of Respiratory and Critical Care Medicine, Bejing Hospital, Beijing, ChinaDepartment of Allergy, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, ChinaDepartment of Dermatology and Venerology, Xijing Hospital, Fourth Military Medical University, Xi'an, ChinaDepartment of Allergy, Peking Union Medical College Hospital, Beijing, ChinaDepartment of Allergy, Henan Provincial Peoples Hospital, Zhengzhou, ChinaDepartment of Allergy, Beijing Children's Hospital Capital Medical University, Beijing, ChinaDepartment of Dermatology and Venerology, The First Hospital of China Medical University, Shenyang, ChinaDepartment of Dermatology and Venerology, Peking University Third Hospital, Beijing, ChinaDepartment of Paediatrics, Peking University First Hospital, Beijing, ChinaDepartment of Otorhinolaryngology Head and Neck Surgery, First Affiliated Hospital of Kunming Medical University, Kunming, ChinaDepartment of Dermatology and Venerology, Peking University Third Hospital, Beijing, ChinaDepartment of Dermatology and Venerology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, ChinaDepartment of Allergy, Tongji Medical College, Huazhong University of Science&Technology, Wuhan, ChinaDepartment of Dermatology and Venerology, The First Hospital of Shanxi Medical University, Taiyuan, ChinaDepartment of Allergy, Shandong Provincial Qianfoshan Hospital, The First Affiliated Hospital of Shandong First Medical University, Shandong Institute of Respiratory Diseases, Jinan, ChinaDepartment of Paediatrics, Peking University Third Hospital, Beijing, ChinaDepartment of Dermatology and Venerology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, ChinaDepartment of Dermatology and Venerology, Peking University First Hospital, Beijing, China; Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin, Berlin, Germany; Corresponding author. Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Charitéplatz 1, D-10117, Berlin, Germany.Chronic urticaria (CU) is a debilitating skin disease that lasts for more than 6 weeks with wheals and/or angioedema, including chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). In China, the prevalence of this disease is high, more than 1%, and on the rise. CU has a major impact on the quality of life (QoL) of patients who frequently experience sleep disturbance, depression, and anxiety. Nearly one-third of patients with CSU, in China, are resistant to second-generation H1-antihistamines (sgAHs), even at a fourfold dose (second line; off-label). Omalizumab is approved for the treatment of CSU treatment in Europe and shows remarkable efficacy and safety. In China, regulatory approval for the use of omalizumab is pending, and its use in clinical practice varies widely. Consensus on omalizumab CU treatment in China is urgently needed. The aim of this article is to propose a practical omalizumab treatment algorithm for the management of antihistamine-resistant CSU and CIndU in adults and special population including children and adolescents, and pregnant or breast feeding women, to guide daily clinical practice in China. In the development of this consensus, an expert group including mainly dermatologists, allergists, but also pulmonologists, ENTs, immunologists, and pediatricians in Allergic Disease Prevention and Control Committee, Chinese Preventive Medicine Association, reviewed the existing evidence and developed consensus on the use of omalizumab in CU patients from China. The goal of this consensus is to assist clinicians in making rational decisions in the management of refractory CU with omalizumab. The key clinical questions covered by the treatment algorithm are: 1) Omalizumab treatment routine strategy in both CSU and CIndU patients; 2) Recommended dose and treatment duration for different age stratification; 3) Treatment duration for CU patients with other allergic comorbidities; 4) Recommendation on omalizumab stopping strategy.http://www.sciencedirect.com/science/article/pii/S1939455121001046Chronic spontaneous urticariaChronic inducible urticariaTreatment algorithmOmalizumabChina |
| spellingShingle | Zuotao Zhao, MD, PhD Tao Cai, MD Hong Chen, MD Liuqing Chen, MD Yudi Chen, MD Xiang Gao, MD Xinghua Gao, MD Songmei Geng, MD Yinshi Guo, MD Fei Hao, MD Guodong Hao, MM Yan Hu, MD Hongzhong Jin, MD Zhehu Jin, MD Chengxin Li, MD Haili Li, MD Jie Li, MD Yanming Li, MD Yunsheng Liang, MD Guanghui Liu, MD Qiang Liu, MD Hai Long, MD Lin Ma, MD Yuanyuan Shang, MM Yuxin Song, MB Zhiqiang Song, MD Xiangyang Su, MD Haijing Sui, MD Qing Sun, MD Yuemei Sun, MB Jianping Tang, MD Xunliang Tong, MD Huiying Wang, MD Gang Wang, MD Lianglu Wang, MD Siqin Wang, MB Li Xiang, MD Ting Xiao, MD Zhiqiang Xie, MD. Leping Ye, MD Yongmei Yu, MM Chunlei Zhang, MD, PhD Litao Zhang, MD Shuchen Zhang, MD, PhD Rui Zheng, MD Lili Zhi, MM Wei Zhou, MD Ying Zou, MD Marcus Maurer, MD Expert consensus on the use of omalizumab in chronic urticaria in China World Allergy Organization Journal Chronic spontaneous urticaria Chronic inducible urticaria Treatment algorithm Omalizumab China |
| title | Expert consensus on the use of omalizumab in chronic urticaria in China |
| title_full | Expert consensus on the use of omalizumab in chronic urticaria in China |
| title_fullStr | Expert consensus on the use of omalizumab in chronic urticaria in China |
| title_full_unstemmed | Expert consensus on the use of omalizumab in chronic urticaria in China |
| title_short | Expert consensus on the use of omalizumab in chronic urticaria in China |
| title_sort | expert consensus on the use of omalizumab in chronic urticaria in china |
| topic | Chronic spontaneous urticaria Chronic inducible urticaria Treatment algorithm Omalizumab China |
| url | http://www.sciencedirect.com/science/article/pii/S1939455121001046 |
| work_keys_str_mv | AT zuotaozhaomdphd expertconsensusontheuseofomalizumabinchronicurticariainchina AT taocaimd expertconsensusontheuseofomalizumabinchronicurticariainchina AT hongchenmd expertconsensusontheuseofomalizumabinchronicurticariainchina AT liuqingchenmd expertconsensusontheuseofomalizumabinchronicurticariainchina AT yudichenmd expertconsensusontheuseofomalizumabinchronicurticariainchina AT xianggaomd expertconsensusontheuseofomalizumabinchronicurticariainchina AT xinghuagaomd expertconsensusontheuseofomalizumabinchronicurticariainchina AT songmeigengmd expertconsensusontheuseofomalizumabinchronicurticariainchina AT yinshiguomd expertconsensusontheuseofomalizumabinchronicurticariainchina AT feihaomd expertconsensusontheuseofomalizumabinchronicurticariainchina AT guodonghaomm expertconsensusontheuseofomalizumabinchronicurticariainchina AT yanhumd expertconsensusontheuseofomalizumabinchronicurticariainchina AT hongzhongjinmd expertconsensusontheuseofomalizumabinchronicurticariainchina AT zhehujinmd expertconsensusontheuseofomalizumabinchronicurticariainchina AT chengxinlimd expertconsensusontheuseofomalizumabinchronicurticariainchina AT haililimd expertconsensusontheuseofomalizumabinchronicurticariainchina AT jielimd expertconsensusontheuseofomalizumabinchronicurticariainchina AT yanminglimd expertconsensusontheuseofomalizumabinchronicurticariainchina AT yunshengliangmd expertconsensusontheuseofomalizumabinchronicurticariainchina AT guanghuiliumd expertconsensusontheuseofomalizumabinchronicurticariainchina AT qiangliumd expertconsensusontheuseofomalizumabinchronicurticariainchina AT hailongmd expertconsensusontheuseofomalizumabinchronicurticariainchina AT linmamd expertconsensusontheuseofomalizumabinchronicurticariainchina AT yuanyuanshangmm expertconsensusontheuseofomalizumabinchronicurticariainchina AT yuxinsongmb expertconsensusontheuseofomalizumabinchronicurticariainchina AT zhiqiangsongmd expertconsensusontheuseofomalizumabinchronicurticariainchina AT xiangyangsumd expertconsensusontheuseofomalizumabinchronicurticariainchina AT haijingsuimd expertconsensusontheuseofomalizumabinchronicurticariainchina AT qingsunmd expertconsensusontheuseofomalizumabinchronicurticariainchina AT yuemeisunmb expertconsensusontheuseofomalizumabinchronicurticariainchina AT jianpingtangmd expertconsensusontheuseofomalizumabinchronicurticariainchina AT xunliangtongmd expertconsensusontheuseofomalizumabinchronicurticariainchina AT huiyingwangmd expertconsensusontheuseofomalizumabinchronicurticariainchina AT gangwangmd expertconsensusontheuseofomalizumabinchronicurticariainchina AT liangluwangmd expertconsensusontheuseofomalizumabinchronicurticariainchina AT siqinwangmb expertconsensusontheuseofomalizumabinchronicurticariainchina AT lixiangmd expertconsensusontheuseofomalizumabinchronicurticariainchina AT tingxiaomd expertconsensusontheuseofomalizumabinchronicurticariainchina AT zhiqiangxiemd expertconsensusontheuseofomalizumabinchronicurticariainchina AT lepingyemd expertconsensusontheuseofomalizumabinchronicurticariainchina AT yongmeiyumm expertconsensusontheuseofomalizumabinchronicurticariainchina AT chunleizhangmdphd expertconsensusontheuseofomalizumabinchronicurticariainchina AT litaozhangmd expertconsensusontheuseofomalizumabinchronicurticariainchina AT shuchenzhangmdphd expertconsensusontheuseofomalizumabinchronicurticariainchina AT ruizhengmd expertconsensusontheuseofomalizumabinchronicurticariainchina AT lilizhimm expertconsensusontheuseofomalizumabinchronicurticariainchina AT weizhoumd expertconsensusontheuseofomalizumabinchronicurticariainchina AT yingzoumd expertconsensusontheuseofomalizumabinchronicurticariainchina AT marcusmaurermd expertconsensusontheuseofomalizumabinchronicurticariainchina |